Skip to main content

Table 1 Results of the cost–effectiveness analyses

From: Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients

 

Lifetime costs (€)

Lifetime QALYs

ICER (€/QALY gained)

Apixaban

Warfarin

Diff.

Apixaban

Warfarin

Diff.

Base case

16,197

15,936

261

7.19

7.05

0.14

1824

Without discounting

20,647

20,442

205

8.99

8.80

0.19

1060

Sensitivity analyses

CHADS 0–1

15,491

14,931

560

7.25

7.12

0.13

4347

CHADS 2

16,151

15,708

443

7.20

7.07

0.13

3387

CHADS 3–6

17,012

17,266

−254

7.13

6.96

0.17

Dominant

TTR < 52.38 %

16,047

17,150

−1104

7.19

6.97

0.22

Dominant

52.38 % ≤ TTR < 66.02 %

17,397

16,170

1226

7.14

7.04

0.10

12,312

66.02 % ≤ TTR < 76.51 %

16,164

15,131

1033

7.20

7.10

0.10

10,386

TTR ≥ 76.51 %

15,150

15,249

−98.23

7.25

7.10

0.15

Dominant

No treatment discontinuations after trial period

19,473

19,042

431

7.24

7.04

0.21

2102

Warfarin monitoring cost −50 %

16,197

14,650

1546

7.19

7.05

0.15

10,817

Warfarin monitoring cost +50 %

16,197

17,222

−1025

7.19

7.05

0.14

Dominant